top of page

REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy

REPROCELL currently has two clinical pipelines under research and development: (1.) the stem cell product Stemchymal for spinocerebellar ataxia; (2.) iPSC-derived neuroglial cells for ALS (Amyotrophic Lateral Sclerosis), and they will soon have a new, third clinical pipeline: (3.) Tumor-infiltrating lymphocyte infusion therapy (TIL therapy) for cervical cancer.


In June 2023, REPROCELL entered into an agreement with the Department of Obstetrics and Gynecology of Keio University School of Medicine, for the development of a new pipeline for TIL therapy in Advanced Medical Treatment B (Tier II clinical trial of short-term cultured anti-tumor lymphocyte infusion therapy using non-destructive bone marrow pre-treatment and low-dose IL-2). Under this agreement, a joint research and development has been conducted.

REPROCELL will act as the cell processing partner for the clinical trial “Advanced Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy) for Cervical Cancer”, which will be jointly conducted by the Department of Obstetrics and Gynecology, Keio University School of Medicine and the International University of Health and Welfare (see Keio University School of Medicine Press Release).

Upon completion of this clinical trial, REPROCELL will commercialize TIL Therapy as their new clinical pipeline.


Other Science, engineering & technology news

bottom of page